About
Cancer Drugs
Areas of Focus
Categories
Small Molecule PharmaceuticalSan Diego & Southern California
Team (15)
Bernd R. Seizinger, M.D., Ph.D.
Board Member
Aptose Biosciences
team_member
Brian Druker, M.D.
Aptose Biosciences
team_member
Daniel D. Von Hoff, M.D., F.A.C.P.
Aptose Biosciences
team_member
Denis R. Burger, Ph.D.
Board Member, Lead Director
Aptose Biosciences
lead_independent_directorboard_member
Erich M. Platzer, M.D., Ph.D.
Board Member
Aptose Biosciences
team_member
Fletcher Payne
Senior Vice President, Chief Financial Officer & Chief Business Officer
Aptose Biosciences
executive
Clinical Trials (8)
View allTotal Trials
8
As Lead Sponsor
8
As Collaborator
0
Total Enrollment
848
By Phase
PHASE1: 4PHASE1/PHASE2: 2PHASE2: 1PHASE3: 1
By Status
COMPLETED: 4TERMINATED: 3RECRUITING: 1
Clinical Trials Pipeline8 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT04477291Lead Sponsor
A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS
PHASE1Terminated
45 participants
Started: Oct 6, 2020 · Completed: Apr 15, 2024
NCT03893682Lead Sponsor
A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
PHASE1Terminated
36 participants
Started: Apr 30, 2019 · Completed: May 17, 2024
NCT03850574Lead Sponsor
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
PHASE1/PHASE2Recruiting
240 participants
Started: Mar 11, 2019 · Completed: Apr 30, 2027
NCT02267863Lead Sponsor
A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS
PHASE1Terminated
21 participants
Started: Oct 31, 2014 · Completed: Sep 30, 2021
NCT01281592Lead Sponsor
A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours
PHASE1Completed
36 participants
Started: Jan 31, 2011 · Completed: Jan 31, 2014
Locations (1)
Headquarters
San Diego, CA, United States
Map
Loading map...